Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety

Exclusion Criteria

• •1\. Secondary RLS (e.g., iron deficiency anemia with serum ferritin \<30μg/L, renal dysfunction with eGFR \<30ml/min, pregnancy/lactation, drug-induced RLS with unadjustable medications).
• •2\. Severe central nervous system diseases (e.g., status epilepticus, severe dementia, stroke within 3 months).
• •3\. Severe cardiovascular diseases (e.g., congestive heart failure, uncontrolled hypertension with SBP≥180mmHg or DBP≥110mmHg).
• •4\. Severe liver or kidney dysfunction (ALT/AST \>3×ULN, eGFR \<30mL/min/1.73m²).
• •5\. Active mental illnesses (e.g., schizophrenia, acute bipolar disorder).
• •6\. Hypersensitivity to Keligabalin Benzenesulfonic Acid or its excipients.
• •7\. Participation in other clinical trials within 1 month, inability to cooperate with follow-up, or history of substance abuse.
• •8\. Pregnancy or lactation.